Gilead Sciences has agreed to pay $2.5 billion to take over Myogen, whose primary drug candidate is its Ambrisentan for treating pulmonary arterial hypertension. The drug is in late-stage trials, and Myogen is expected to apply for approval in the fourth quarter. Gilead executives cited the drug, which they say addresses an unmet medical need, as a driving reason behind the purchase.

Related Summaries